NanoPhoria, a pre-clinical stage biotech company developing a versatile and non-viral drug delivery platform based on inorganic nanoparticles with a lead product for heart failure treatment, announces the investment commitment of €17.5 million from the European Innovation Council’s (EIC) Accelerator program, including a grant of €2.5 million and a conditional equity investment of up to €15 million.
NanoPhoria’s platform enables selective organ and/or cellular targeting. The core vehicle of the platform is an inorganic calcium-phosphate nanoparticle that is a versatile, non-viral, biomimetic nano-carrier that can be loaded with active biologics. And the lead product coming out of the platform is a treatment for heart failure with reduced ejection fraction (HFrEF), a chronic syndrome affecting the lives of millions worldwide.
NanoPhoria will extend its research into clinical trials to translate initial remarkable preclinical observations into better treatment options and a potential paradigm change in the treatment of heart failure.
KEY QUOTES:
“This prestigious recognition along with the investment support from the EIC underscores the potential value of NanoPhoria’s unique and disruptive technology and will help advance our lead product for heart failure which has the potential to make a significant impact on patient outcomes. This product has already shown impressive efficacy in pre-clinical models, and we are eager to rapidly develop it for use in patients.”
– Claudio De Luca, NanoPhoria’s co-founder and Chief Executive Officer
“I am impressed by the progress made by NanoPhoria, their selection to receive the highly prestigious EIC Accelerator funding is richly deserved. We are catalyzing breakthrough innovation in heart failure by progressing our lead product to first in human studies, and we have the potential to deliver a variety of biologics through our unique non-viral nano-in-micro and lung-to-heart technology platform.”
– Suman Shirodkar, Chairman of NanoPhoria’s Board of Directors
“The company has made great progress since our initial investment in spring 2022. We are delighted to see them secure funding from the highly competitive EIC Accelerator, propelling them to achieve their full potential.”
– Lucia Faccio, a Partner at Sofinnova Partners
